Literature DB >> 28608641

Risk factors for Pneumocystis pneumonia after the first 6 months following renal transplantation.

Emmanuel Faure1, Arnaud Lionet1, Eric Kipnis2, Christian Noël1, Marc Hazzan1.   

Abstract

Pneumocystis pneumonia (PCP) incidence was decreased in renal transplant thanks to prophylaxis, recommended during the first months after transplantation. However, many late PCP cases are observed after the first 6 months and recommendations to maintain or reintroduce prophylaxis are lacking. The objective of the study was to identify risk factors to guide the individual prescription of prophylaxis, 6 months after transplantation. Thirty-three late PCP cases were identified between 1995 and 2012 in Lille Hospital, France, and were compared to 72 randomized controls transplant recipients. In univariate analysis, age of donor (>48 years), retransplantation, a decrease glomerular filtration rate (≤45 mL/min), induction therapy mediated by anti-thymocyte globulin (ATG), steroid maintenance, high calcineurin inhibitors (CNI) doses (tacrolimus ≥0.5 mg/kg/day and cyclosporine ≥2.1 mg/kg/day), and cytomegalovirus (CMV) infection were significantly associated with PCP. In multivariate analysis, ATG (hazard ratio [HR]: 2.4 [1.1-5.4]), steroid therapy (HR: 3.1 [1.20-7.84], CNI (HR: 2.9 [1.28-6.38], and CMV (HR: 6.1 [2.74-16.33] remained associated with late PCP. In conclusion, we confirm that intensive immunosuppressive regimen and CMV infection are critical risk factors for late PCP and should be taken into account to decide on maintenance or reintroduction of a prophylactic treatment.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Pneumocystis; immunosuppression; renal recipient; risk factors

Mesh:

Year:  2017        PMID: 28608641     DOI: 10.1111/tid.12735

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  5 in total

1.  Comparison of early and late Pneumocystis jirovecii Pneumonia in kidney transplant patients: the Korean Organ Transplantation Registry (KOTRY) Study.

Authors:  Gongmyung Lee; Tai Yeon Koo; Hyung Woo Kim; Dong Ryeol Lee; Dong Won Lee; Jieun Oh; Beom Seok Kim; Myoung Soo Kim; Jaeseok Yang
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

2.  Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab.

Authors:  Young Hoon Kim; Jee Yeon Kim; Dong Hyun Kim; Youngmin Ko; Ji Yoon Choi; Sung Shin; Joo Hee Jung; Su-Kil Park; Sung-Han Kim; Hyunwook Kwon; Duck Jong Han
Journal:  BMC Nephrol       Date:  2020-03-11       Impact factor: 2.388

3.  Successful treatment of a kidney transplant patient with COVID-19 and late-onset Pneumocystis jirovecii pneumonia.

Authors:  Jing Peng; Ming Ni; Dunfeng Du; Yanjun Lu; Juan Song; Weiyong Liu; Na Shen; Xiong Wang; Yaowu Zhu; Bruce A Vallance; Ziyong Sun; Hong Bing Yu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-12-15       Impact factor: 3.944

4.  Distinct Clinical and Laboratory Patterns of Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients.

Authors:  Andreas M J Meyer; Daniel Sidler; Cédric Hirzel; Hansjakob Furrer; Lukas Ebner; Alan A Peters; Andreas Christe; Uyen Huynh-Do; Laura N Walti; Spyridon Arampatzis
Journal:  J Fungi (Basel)       Date:  2021-12-13

5.  Clinical descriptive analysis of severe Pneumocystis jirovecii pneumonia in renal transplantation recipients.

Authors:  Dan Xie; Wen Xu; Jingya You; Xiaofeng Yuan; Mingliang Li; Xiaogang Bi; Kouxing Zhang; Heng Li; Ying Xian
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.